AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
Gilead Sciences has finalized its $7.8 billion acquisition of Arcellx, Inc., positioning the company for the potential 2026 commercial launch of the BCMA-directed CAR T-cell therapy, anito-cel.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Eli Lilly and Company expands its oncology portfolio through the Lilly Ajax Therapeutics acquisition, targeting breakthroughs in myeloproliferative neoplasms with AJ1-11095.
Sun Pharmaceutical Industries has announced a definitive agreement to acquire Organon & Co. for $11.75 billion, marking a major expansion into women’s health and biosimilars.
The Foundayo launch impact on Eli Lilly has been swift and sharp — while FDA approval of orforglipron marked a historic first for oral GLP-1 obesity treatment, early prescription data trailing Novo Nordisk’s Wegovy sent LLY stock down as much as 4.3%, forcing analysts to slash 2026 revenue forecasts from $5 billion to just $1.3–1.6 billion.
Johnson & Johnson Atraverse Medical’s acquisition marks a significant milestone in the field of electrophysiology. Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to [Read More…]
Labcorp has announced nationwide availability for the Agilent PD-L1 IHC 22C3 pharmDx, a critical companion diagnostic for identifying ovarian cancer patients eligible for Merck’s KEYTRUDA therapy.
Merck receives Idvynso FDA approval for its once-daily single-tablet regimen of doravirine and islatravir. This breakthrough treatment offers a new option for adults living with HIV-1 who are virologically suppressed.
Sanofi has achieved a historic breakthrough with the expanded Tzield FDA approval for young children. Previously restricted to those aged eight and older, the therapy is now available for children as young as one year old, offering a vital window to delay the onset of clinical Type 1 Diabetes.
